TREATMENT OF ACQUIRED FACTOR VIII INHIBITOR VIA RECOMBINANT ACTIVATED FACTOR VIIa: DATA FROM THE ITALIAN REGISTRY OF ACQUIRED HEMOPHILIA

Abstract

We report on the data collected in the Italian Registry of acquired haemophilia (AH) in 2001. Recombinant activated factor VII (rFVIIa) was selected as first-line therapy in 19 bleeding episodes because of their severity and as salvage in one case. Bleeding was controlled in 90% of the episodes, indicating the efficacy of rFVIIa in HA